RxDoctor Payments Data

John Bennett, MD

Family Medicine · Forest City, NCNPI 1033189717

Payments from drug & device makers

$1,151in general payments, 2019–2025

Across 70 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$293
  • AstraZeneca$165
  • GSK$157
  • Biohaven Pharmaceutical Holding Company Ltd.$72
  • Novartis$70
  • Johnson & Johnson$57
  • plus $336 from 11 others

What the payments were for

  • Food & beverage$1,151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,151 in reported general payments places this provider in the 70th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$121,031
Medicare patients
288
Services billed
2,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$159,115
OzempicSemaglutide67$79,826
XareltoRivaroxaban70$69,810
FarxigaDapagliflozin Propanediol72$55,603
JardianceEmpagliflozin59$54,479
TrulicityDulaglutide46$52,030
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$51,630
Tresiba Flextouch U-200Insulin Degludec34$39,125
InvokanaCanagliflozin27$32,332
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog43$22,824
MyrbetriqMirabegron39$21,060
Breo ElliptaFluticasone/Vilanterol41$20,446
LinzessLinaclotide16$16,710
Soliqua 100-33Insulin Glargine/Lixisenatide12$13,654
JanuviaSitagliptin Phosphate11$13,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$159,115210 claims
Johnson & JohnsonXarelto, Invokana$57$102,14297 claims
Novo NordiskOzempic, Rybelsus$293$90,54178 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$157$75,09699 claims
AstraZenecaFarxiga$165$55,60372 claims
Lilly USA, LLCTrulicity$54$52,03046 claims
Astellas Pharma US IncMyrbetriq$31$21,06039 claims
AbbVieLinzess, Synthroid$40$18,73441 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$14$13,65412 claims
MerckJanuvia$32$13,61911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Forest City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →